Cryocell International Stock Analysis
| CCEL Stock | USD 3.43 0.06 1.78% |
IPO Date 21st of January 1997 | 200 Day MA 4.4224 | 50 Day MA 3.565 | Beta 0.654 |
CryoCell International holds a debt-to-equity ratio of 0.255. Short Term Debt is expected to rise to about 5 M this year, although the value of Net Debt will most likely fall to about 10.6 M. CryoCell International's financial risk is the risk to CryoCell International stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
CryoCell International's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. CryoCell International's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps CryoCell Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect CryoCell International's stakeholders.
For many companies, including CryoCell International, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for CryoCell International, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, CryoCell International's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Price Book 9.7236 | Enterprise Value Ebitda 7.1676 | Price Sales 0.8695 | Shares Float 4.2 M | Dividend Share 0.65 |
CryoCell International is undervalued with Real Value of 4.61 and Target Price of 8.5. The main objective of CryoCell International stock analysis is to determine its intrinsic value, which is an estimate of what CryoCell International is worth, separate from its market price. There are two main types of CryoCell International's stock analysis: fundamental analysis and technical analysis.
The CryoCell International stock is traded in the USA on NYSE MKT Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CryoCell International. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in discontinued. CryoCell Stock Analysis Notes
About 42.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.06. CryoCell International last dividend was issued on the 21st of May 2025. Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida. Cryo-Cell Intl operates under Medical Care Facilities classification in the United States and is traded on AMEX Exchange. It employs 83 people. For more info on CryoCell International please contact Mark Portnoy at 813 749 2100 or go to https://www.cryo-cell.com.CryoCell International Quarterly Total Revenue |
|
CryoCell International Investment Alerts
| CryoCell International generated a negative expected return over the last 90 days | |
| CryoCell International has high historical volatility and very poor performance | |
| CryoCell International currently holds 12.93 M in liabilities with Debt to Equity (D/E) ratio of 0.26, which may suggest the company is not taking enough advantage from borrowing. CryoCell International has a current ratio of 0.46, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about CryoCell International's use of debt, we should always consider it together with its cash and equity. | |
| About 42.0% of CryoCell International shares are held by company insiders | |
| Latest headline from news.google.com: Is Cryo Cell International Inc. stock forming a triangle pattern - Breakout Watch Smart Money Movement Tracker - mfd.ru |
CryoCell Largest EPS Surprises
Earnings surprises can significantly impact CryoCell International's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-07-14 | 2025-05-31 | 0.03 | 0.04 | 0.01 | 33 | ||
2024-07-15 | 2024-05-31 | 0.04 | 0.08 | 0.04 | 100 | ||
2024-04-15 | 2024-02-29 | -0.02 | 0.07 | 0.09 | 450 |
CryoCell International Environmental, Social, and Governance (ESG) Scores
CryoCell International's ESG score is a quantitative measure that evaluates CryoCell International's performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of CryoCell International's operations that may have significant financial implications and affect CryoCell International's stock price as well as guide investors towards more socially responsible investments.
CryoCell Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Jones Financial Companies Lllp | 2025-06-30 | 1.3 K | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 601 | Tower Research Capital Llc | 2025-06-30 | 464 | Compass Financial Services Inc | 2025-06-30 | 200 | Signaturefd, Llc | 2025-06-30 | 100.0 | Ubs Group Ag | 2025-06-30 | 100.0 | Bank Of America Corp | 2025-06-30 | 37.0 | Jpmorgan Chase & Co | 2025-06-30 | 11.0 | Sbi Securities Co Ltd | 2025-06-30 | 2.0 | Hamilton Lane Advisors Llc | 2025-06-30 | 409.7 K | Sfi Advisors, Llc | 2025-06-30 | 165.3 K |
CryoCell Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 27.61 M.CryoCell Profitablity
The company has Profit Margin (PM) of (0.01) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.24 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.24.| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.01 | 0.01 | |
| Return On Capital Employed | 0.07 | 0.08 | |
| Return On Assets | 0.01 | 0.01 | |
| Return On Equity | (0.04) | (0.04) |
Management Efficiency
CryoCell International has return on total asset (ROA) of 0.0429 % which means that it generated a profit of $0.0429 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 1.292 %, meaning that it created $1.292 on every $100 dollars invested by stockholders. CryoCell International's management efficiency ratios could be used to measure how well CryoCell International manages its routine affairs as well as how well it operates its assets and liabilities. At this time, CryoCell International's Return On Tangible Assets are quite stable compared to the past year. Return On Capital Employed is expected to rise to 0.08 this year, although the value of Return On Equity will most likely fall to (0.04). At this time, CryoCell International's Return On Tangible Assets are quite stable compared to the past year. Return On Assets is expected to rise to 0.01 this year, although the value of Other Current Assets will most likely fall to about 1.1 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (1.87) | (1.78) | |
| Tangible Book Value Per Share | (2.27) | (2.16) | |
| Enterprise Value Over EBITDA | 66.97 | 63.62 | |
| Price Book Value Ratio | (6.13) | (5.83) | |
| Enterprise Value Multiple | 66.97 | 63.62 | |
| Price Fair Value | (6.13) | (5.83) | |
| Enterprise Value | 95.3 M | 90.5 M |
CryoCell International benefits from a proactive management team that anticipates market trends. Our analysis delves into how this proactive stance influences financial metrics and stock valuation.
Technical Drivers
As of the 15th of February 2026, CryoCell International shows the Risk Adjusted Performance of (0.07), mean deviation of 2.14, and Standard Deviation of 3.08. CryoCell International technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm CryoCell International market risk adjusted performance, variance, as well as the relationship between the Variance and value at risk to decide if CryoCell International is priced correctly, providing market reflects its regular price of 3.43 per share. Given that CryoCell International has information ratio of (0.11), we suggest you to validate CryoCell International's prevailing market performance to make sure the company can sustain itself at a future point.CryoCell International Price Movement Analysis
java.lang.NullPointerException: Cannot invoke "java.lang.Number.intValue()" because the return value of "sun.invoke.util.ValueConversions.primitiveConversion(sun.invoke.util.Wrapper, Object, boolean)" is null. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. CryoCell International middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for CryoCell International. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
CryoCell International Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific CryoCell International insiders, such as employees or executives, is commonly permitted as long as it does not rely on CryoCell International's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases CryoCell International insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
CryoCell International Outstanding Bonds
CryoCell International issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. CryoCell International uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most CryoCell bonds can be classified according to their maturity, which is the date when CryoCell International has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
CryoCell International Predictive Daily Indicators
CryoCell International intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of CryoCell International stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
CryoCell International Forecast Models
CryoCell International's time-series forecasting models are one of many CryoCell International's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary CryoCell International's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.CryoCell International Bond Ratings
CryoCell International financial ratings play a critical role in determining how much CryoCell International have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for CryoCell International's borrowing costs.| Piotroski F Score | 6 | Healthy | View |
| Beneish M Score | (2.21) | Possible Manipulator | View |
CryoCell International Debt to Cash Allocation
Many companies such as CryoCell International, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
CryoCell International currently holds 12.93 M in liabilities with Debt to Equity (D/E) ratio of 0.26, which may suggest the company is not taking enough advantage from borrowing. CryoCell International has a current ratio of 0.46, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about CryoCell International's use of debt, we should always consider it together with its cash and equity.CryoCell International Total Assets Over Time
CryoCell International Assets Financed by Debt
The debt-to-assets ratio shows the degree to which CryoCell International uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.CryoCell International Debt Ratio | 22.0 |
CryoCell International Corporate Bonds Issued
CryoCell Net Debt
Net Debt |
|
About CryoCell Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how CryoCell International prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling CryoCell shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as CryoCell International. By using and applying CryoCell Stock analysis, traders can create a robust methodology for identifying CryoCell entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | 0.08 | 0.08 | |
| Operating Profit Margin | 0.10 | 0.10 | |
| Net Profit Margin | 0.01 | 0.01 | |
| Gross Profit Margin | 0.68 | 0.56 |
Current CryoCell Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. CryoCell analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. CryoCell analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Consensus | # of Analysts | |
| 8.5 | Buy | 1 | Odds |
Most CryoCell analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand CryoCell stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of CryoCell International, talking to its executives and customers, or listening to CryoCell conference calls.
CryoCell Stock Analysis Indicators
CryoCell International stock analysis indicators help investors evaluate how CryoCell International stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading CryoCell International shares will generate the highest return on investment. By understating and applying CryoCell International stock analysis, traders can identify CryoCell International position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 406.1 K | |
| Total Stockholder Equity | -13.2 M | |
| Capital Lease Obligations | 933.4 K | |
| Property Plant And Equipment Net | 22.7 M | |
| Cash And Short Term Investments | 3.5 M | |
| Cash | 561 K | |
| 50 Day M A | 3.565 | |
| Net Interest Income | -1.9 M | |
| Total Current Liabilities | 21.6 M | |
| Investments | -4.9 M | |
| Interest Expense | 1.9 M | |
| Stock Based Compensation | 781.1 K | |
| Long Term Debt | 8.3 M | |
| Common Stock Shares Outstanding | 8.2 M | |
| Total Cashflows From Investing Activities | -4.9 M | |
| Tax Provision | 2.4 M | |
| Quarterly Earnings Growth Y O Y | -0.308 | |
| Other Current Assets | 1.1 M | |
| Accounts Payable | 1.9 M | |
| Net Debt | 12.4 M | |
| Other Operating Expenses | 28.5 M | |
| Non Current Assets Total | 52.1 M | |
| Liabilities And Stockholders Equity | 64.7 M | |
| Non Currrent Assets Other | 5.8 M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CryoCell International. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in discontinued. For more information on how to buy CryoCell Stock please use our How to buy in CryoCell Stock guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CryoCell International. Projected growth potential of CryoCell fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive CryoCell International assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth (0.31) | Dividend Share 0.65 | Earnings Share (0.06) | Revenue Per Share | Quarterly Revenue Growth (0.03) |
Investors evaluate CryoCell International using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating CryoCell International's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause CryoCell International's market price to deviate significantly from intrinsic value.
It's important to distinguish between CryoCell International's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding CryoCell International should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, CryoCell International's market price signifies the transaction level at which participants voluntarily complete trades.